The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at ...

One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...